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Abstract
Background: American Trypanosomiasis or Chagas disease is caused by Trypanosoma cruzi which
currently infects approximately 16 million people in the Americas causing high morbidity and
mortality. Diagnosis of American trypanosomiasis relies on serology, primarily using indirect
immunofluorescence assay (IFA) with T. cruzi epimastigote forms. The closely related but
nonpathogenic Trypanosoma rangeli has a sympatric distribution with T. cruzi and is carried by the
same vectors. As a result false positives are frequently generated. This confounding factor leads to
increased diagnostic test costs and where false positives are not caught, endangers human health
due to the toxicity of the drugs used to treat Chagas disease.
Results: In the present study, serologic cross-reactivity between the two species was compared
for the currently used epimastigote form and the more pathologically relevant trypomastigote
form, using IFA and immunoblotting (IB) assays. Our results reveal an important decrease in cross
reactivity when T. rangeli culture-derived trypomastigotes are used in IFA based diagnosis of Chagas
disease. Western blot results using sera from both acute and chronic chagasic patients presenting
with cardiac, indeterminate or digestive disease revealed similar, but not identical, antigenic
profiles.
Conclusion: This is the first study addressing the serological cross-reactivity between distinct
forms and strains of T. rangeli and T. cruzi using sera from distinct phases of the Chagasic infection.
Several T. rangeli-specific proteins were detected, which may have potential as diagnostic tools.
Background
Trypanosoma rangeli and  Trypanosoma cruzi are closely
related and sympatric protozoan parasites that infect tri-
atomine bugs, humans and a variety of sylvatic and
domestic mammals in overlapping regions of both South
and Central America [1-3]. T. rangeli is nonpathogenic to
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humans while T. cruzi is the etiological agent of Chagas
disease and infects over 16 million people in the new
world [4]. Unsurprisingly, given the sympatric distribu-
tion and shared vector and host range, mixed infections
are observed [1-3].
T. rangeli is considered a parasite of biological and epide-
miological interest due to the serological cross-reactivity
with T. cruzi, which has been the subject of great contro-
versy [5-8]. Several reports pointed out the sharing of anti-
genic epitopes by T. cruzi and T. rangeli [9-12]. However,
these studies were performed with sera from animals
immunized with T. rangeli epimastigotes rather than
infected or immunized with the trypomastigote forms
present in infected hosts [9-12]. It is widely accepted to
have an outstanding but underestimated impact on the
diagnosis of Chagas disease [2,9-14].
A recent study on T. cruzi serodiagnosis reported the
absence of cross-reaction of T. rangeli-infected patient's
sera in some commercially available ELISA tests [15].
Despite the fact that PCR-based diagnosis can provide
accurate discrimination of T. cruzi from T. rangeli [2,3],
neither method is widespread in the diagnostic laborato-
ries of endemic areas where IFA of cultured T. cruzi epi-
mastigote forms with patient sera remains the screening
method of choice [16-18]. The use of at least two serolog-
ical tests based on different methods, mandatory in Brazil
for almost two decades now [17], have enhanced the sen-
sitivity detection. Comparative studies of the antigenic
composition of culture-derived T. cruzi and T. rangeli epi-
mastigote forms indicate that these parasites share
approximately 60% of their soluble antigenic composi-
tion [5,7,11] often resulting in a significant level of incon-
clusive results [17].
Epimastigote forms are not seen in the blood of infected
individuals and are therefore not the form against which
antibody develops, rather the forms seen on blood smears
are normally the trypomastigote forms. We considered
therefore, whether serum screening using trypomastigotes
from culture, rather than epimastigotes, would help to
reduce misdiagnosis. We extended these studies to exam-
ine the expression of cross-reactive proteins between life
cycle stages in order to reveal candidate proteins for
molecular diagnostics, pathogenicity factors and possible
vaccines.
Results
Independent of the clinical form, all chagasic sera tested
reacted with both T. cruzi and T. rangeli epimastigotes in
IFA (Figs. 1 and 2). Considering reactions with titers over
1:40 as positive, cross-reactions were observed for 88.46%
of the serum from patients with the cardiac form of the
Chagas disease (Fig. 2). Interestingly, the use of T. rangeli
trypomastigote forms as antigen reduced the cross-reactiv-
ity of serum from patients with the cardiac form of the
Chagas disease to 30.76% (8/26). The titres as well as the
fluorescence intensities were variable depending on the
parasite species and/or strains used but, irrespective of the
form used as antigen, higher titres were obtained for T.
cruzi strains (Fig. 2).
Except for the distinct and significant reactivity (p < 0.05)
of serum from patients with the cardiac form of the Cha-
gas disease with T. cruzi trypomastigotes from the CL or Y
strains, no other significant intra-specific variation of the
reaction titres (p > 0.05) was observed among the strains
studied and the fluorescence pattern revealed was homo-
geneous (Fig. 2). However, inter-specific comparisons
revealed a variable fluorescence pattern and significantly
different (p < 0.001) reaction titres between T. cruzi and T.
rangeli strains for the tested sera, especially when using
trypomastigotes as antigens (Fig. 2).
A representation of the fluorescence patterns observed in
IFA is shown in Figure 1. Both T. cruzi forms showed a flu-
orescence pattern varying from homogeneous cellular,
including nucleus and kinetoplast when tested against
sera from patients with indeterminate form of the disease
(data not shown), to strong plasma membrane labeling
alone when tested with serum from patients with cardiac
involvement (Fig. 1). Sera from all chagasic patients
showed strong membrane fluorescence when tested
against  T. rangeli epimastigotes (Fig. 1) although, sera
from the indeterminate form patients that reacted with T.
cruzi epimastigote forms at 1:40 or 1:80 dilutions resulted
in negative results when tested against T. rangeli epimas-
tigotes at these concentrations (Data not shown).
As expected, chagasic sera gave the strongest reaction with
T. cruzi trypomastigotes regardless of patient clinical his-
tory (Fig. 2). The use of trypomastigote forms from both
species in IFA showed a significant decrease (p < 0.001) in
cross-reactivity when compared to the results obtained for
epimastigote forms (Fig. 2). Also, a significant intra-spe-
cific variation (p < 0.05) of the reaction titers was
observed among epimastigotes of the distinct T. cruzi
strains according to the testing sera (cardiac or indetermi-
nate), which was not observed among the trypomastigote
forms (Fig. 2).
Sera from chronic chagasic patients (cardiac or indetermi-
nate forms) showing borderline titers of 1:40 or 1:80
against T. cruzi epimastigotes, which did not react with T.
rangeli epimastigotes, revealed negative results in IFA with
both T. rangeli and T. cruzi trypomastigotes.
Comparative SDS-PAGE analysis revealed a protein pat-
tern varying from 24 to 110 kDa for both Trypanosoma spe-Parasites & Vectors 2008, 1:20 http://www.parasitesandvectors.com/content/1/1/20
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cies (Fig. 3A). Epimastigote forms gave similar patterns,
sharing a large number of prominent and faint bands. For
trypomastigotes though, it was possible to visualize differ-
ences in the electrophoretic profiles (Fig. 3A, lanes 2 and
4). No major differences were observed among the pro-
files of both T. rangeli forms, however, the profile of T.
cruzi epimastigotes revealed two major proteins around
36 and 52 kDa, as also observed on both T. rangeli forms,
which were present in much lower intensity on the T. cruzi
trypomastigotes profile (Fig. 3A).
Immunoblot analysis using all acute and chronic chagasic
patient sera recognized a wide range of proteins in both
parasite species and strains (data not shown), revealing a
quite distinct inter-specific pattern. A representation of
the obtained results is shown on Fig. 3B. Sera from
patients in the acute phase of Chagas disease recognized
fewer proteins on T. rangeli extracts than sera from chronic
chagasic patients. Two proteins of approximately 32 and
40 kDa were strongly recognized by chagasic sera (acute
and chronic) on T. cruzi extracts (Fig. 3B, dark arrows), but
were not detected in T. rangeli lysates by acute sera. A 32
kDa protein was, though, weakly recognized in chronic
patient sera. Also, some intra-specific differences on anti-
genic profile between T. cruzi Y strain epimastigote and
trypomastigote forms were observed (Fig. 3B).
Signal intensity for several T. rangeli antigens was variable
between chagasic sera. Interestingly, though, a very strong
band of approximately 35 kDa was recognized in both T.
rangeli forms by sera from chronic patients (Fig. 3B, white
arrow).
We further considered whether chagasic sera from differ-
ent pathologies showed similar antigenic profiles by uti-
lizing sera from patients presenting the cardiac,
indeterminate or digestive forms of the disease (Fig. 3C).
Our results revealed very similar profiles for T. cruzi epi-
mastigotes and trypomastigotes but a quite distinct pro-
tein patterns for T. rangeli epimastigotes and
trypomastigotes, independently of the tested sera. Impor-
tantly, a 35 kDa protein was recognized strongly by all
The use of trypomastigotes give better specificity than epimastigotes by IFA Figure 1
The use of trypomastigotes give better specificity than epimastigotes by IFA. Indirect immunofluorescence assay 
using Trypanosoma cruzi and Trypanosoma rangeli trypomastigote or epimastigote forms as antigens and serum (1:80) from a 
chronic chagasic patient with the cardiac form of the disease. Negative controls consist of epimastigotes and non-infected 
patient serum (1:40).
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chagasic sera (Fig. 3C, white arrows). Two proteins of
around 11 and 15 kDa were recognized by the cardiac and
digestive serum in both T. rangeli forms, but not by the
indeterminate sera (Fig. 3C, black arrows).
Discussion
Despite the proven cross-reactions and the existence of
more sensitive and reliable techniques for diagnosis such
as ELISA associated to the use of recombinant antigens,
IFA is still the most widely used method for Chagas dis-
ease diagnosis in Brazil, as in several Latin American
Countries [16-18]. Thus, in the present study the serolog-
ical cross-reactivity between T. cruzi and T. rangeli, epimas-
tigote and trypomastigote forms, was evaluated by IFA
and IB assays using sera of both acute and chronic cha-
gasic patients with different clinical manifestations.
Former studies have shown the serological cross-reactivity
between T. cruzi and T. rangeli epimastigotes by IFA, ELISA
and/or IB assays, pointing that such cross-reactivity is due
the great number of soluble antigens shared by both par-
asites [5,7,9-12,19]. Furthermore, sera from T. cruzi-
infected patients can cross-react with other trypanosoma-
tid species such as T. evansi [20] and Leishmania spp. [15]
as demonstrated by western-blot, ELISA and TESA-Blot,
including some commercially available kits.
In the present study we have confirmed cross-reactivity in
a range of distinct serum samples and also observed that
T. cruzi and T. rangeli epimastigotes reacted with all tested
sera regardless of the clinical presentation of the patient.
However, the fluorescence intensity and pattern produced
by the sera in IFA on parasites cells appeared to be variable
Trypomastigotes discriminate Trypanosoma cruzi from Trypanosoma rangeli over an increased titre range Figure 2
Trypomastigotes discriminate Trypanosoma cruzi from Trypanosoma rangeli over an increased titre range. Com-
parison of antibody titers obtained for chronic chagasic patients serum with cardiac or indeterminate forms tested against epi-
mastigote or trypomastigote forms of T. cruzi Y (open bar) and CL (dotted bar) strains and T. rangeli Choachi (vertical lined 
bar) and SC-58 (horizontal lined bar) strains in indirect immunofluorescence assays. Experiments were performed in duplicates 
and vertical bars above data indicate mean standard error. Horizontal dotted lines indicate the 1:40 cut-off.
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depending on the parasite species and life-cycle stage and
upon the type of serum used. Such differences may be
attributed both to the distinct antibody profiles of the
sera, which in turn can be related to the disease form and/
or to the patient immune response, as well as to the differ-
ences in gene expression and antigenic composition of the
parasites themselves.
It is well established that distinct profiles of anti-T. cruzi
antibodies may be elicited by patients with different clin-
ical presentations of the disease [21-23]. This variable
response pattern can be due to a variety of immune
response related mechanisms, such as the regulation of
immunoglobulin expression. Such differences can pre-
sumably influence the pathogenesis of disease and hence
Immunoblot profiles of Trypanosoma cruzi (Y strain) and Trypanosoma rangeli (Choachi strain) with chagasic sera Figure 3
Immunoblot profiles of Trypanosoma cruzi (Y strain) and Trypanosoma rangeli (Choachi strain) with chagasic 
sera. Total protein extracts resolved in a 12% SDS-PAGE and stained by Comassie brilliant blue (A) and the immunoblot anal-
ysis of the same lysates using sera from acute and chronic chagasic patients (B) or using sera from chronic chagasic patients 
with the cardiac, indeterminate or digestive forms of the disease (C). On panel B, arrows indicates proteins recognized by cha-
gasic sera (acute and/or chronic) on T. cruzi (dark arrows) or on T. rangeli (white arrow) extracts. Arrows in panel C indicates 
a T. rangeli 11 and 15 kDa proteins exclusively recognized by the cardiac and digestive serum in both T. rangeli forms (dark 
arrows) and a 35 kDa protein (white arrows) recognized by all sera from T. cruzi-infected patients. Lanes 1 and 2 = T. cruzi Y 
strain epimastigote and trypomastigote forms and lanes 3 and 4 = T. rangeli Choachi strain epimastigote and trypomastigote 
forms, respectively. Lane 5 = Vero cells extract; MW = molecular weight marker (kDa). Asterisks indicates significant differ-
ences (p < 0.05).
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it clinical presentation but also have implications for the
effectiveness of diagnostic serology [21,23,24].
Despite the antigenic similarity of T. cruzi and T. rangeli,
several studies have described species-specific polypep-
tides allowing specific differentiation of these parasites
[25-27]. Our observations account for both the inter- and
intra-specific differences observed in IFA, identifying a
variety of antigens which are specific not only to species
but also to strains and life cycle stages.
Even considering the antigenic differences to blood trypo-
mastigotes, the use of culture-derived trypomastigotes in
IFAs in this study significantly reduced the serological
cross-reactivity between T. cruzi and T. rangeli (Figs. 1 and
2). It is clear also, though, that even in trypomastigote
forms significant numbers of positive reactive antigens
remain (Figs. 3B and 3C).
Regardless of the clinical presentation from which it is
obtained, sera from chronic chagasic patients revealed a
significantly more intense reaction (p < 0.01) against T.
cruzi trypomastigotes in IFA when compared with epimas-
tigote forms (Figs. 1 and 2). This difference can be
explained by the antibody specificity, since anti-trypo-
mastigote antibodies present on the evaluated sera were
produced against blood trypomastigotes during T. cruzi
infection.
Sera from patients with the indeterminate form of Chagas
disease that showed lower titers (1:40 – 1:80) against T.
cruzi epimastigotes did not recognize T. cruzi and T. rangeli
trypomastigote forms (Fig. 2). Since 76% of the sera from
chagasic patients revealed titres equal or in excess of
1:640, but only 1.4% showed titers below 1:160, and
since all sera with high titres reacted with both epimastig-
ote and trypomastigote forms of T. cruzi and T. rangeli we
conclude that sera with titers below 1:40 are most likely to
be false-positive results.
Thus, considering that Chagas disease diagnosis is prima-
rily based in IFA and/or ELISA assays and that variable
result may be obtained depending on the antigens and
methods used [7,15,20] the use of culture-derived trypo-
mastigote forms as antigens could reduce misdiagnosis of
the disease and the related disability-adjusted life years or
DALY's [28,29].
Nevertheless, the use of such infective forms may repre-
sent an increased risk to those culturing the organisms as
well as an increase in the costs of the diagnostic exams.
These drawbacks reinforce the need to generate recom-
binant antigens or synthetic peptides for specific diagno-
sis [15].
Previous studies have pointed some species-specific anti-
gens allowing specific detection of T. cruzi [30-32] or dif-
ferentiation of T. cruzi and T. rangeli [7,25,26] while other
antigens seem to be shared by distinct Trypanosoma spe-
cies. Among these studies, Saldaña et al. [26,27] have
compared total epimastigote extracts from T. cruzi and T.
rangeli by SDS-PAGE and pointed out T. rangeli exclusive
proteins of approximately 93, 77-73, 63, 54-53 and 48
kDa.
In our present work we have used sera from both acute
patients and chronic chagasic patients with distinct clini-
cal presentations (Figs. 3B and 3C), as well as different
parasite life-cycle stages (epimastigotes and trypomastig-
otes), being the first comparative analysis of trypomastig-
ote antigens of both species.
In order to identify possible species-specific antigens
present in both T. cruzi and T. rangeli life-cycle stages, IB
assays were initially performed using sera from patients
acutely and chronically infected with T. cruzi. These exper-
iments addressed the possibility of discriminating stage-
specific or clinical presentation-specific antigens. The
results indicated at least two proteins present in both T.
cruzi life cycle stages but were absent in T. rangeli (Fig. 3B)
and that were strongly recognized by acute and chronic
sera. These proteins of approximately 32 and 40 kDa,
could represent good targets for the development of spe-
cific recombinant antigens, improving the diagnosis of T.
cruzi in relation to T. rangeli. In addition, a 35 kDa protein
was exclusively observed on both T. rangeli forms extracts
and may also represent a new diagnostic marker candi-
date. However, the amino acid sequence of the exclusive
proteins described in the present study as well as their
conservation among distinct strains remains to be
addressed.
In the present study, the antigenic detection using sera
from chronic patients showed the richest protein profile
when compared to sera from acute patients reinforcing
the results of previous studies [24,30]. However, some
proteins bands between 22 and 50 kDa (Fig. 3C) were
observed in both parasite species and forms regardless of
the sera used. Such proteins may constitute antigens that
elicit antibodies production in all phases and/or forms of
the disease, which could be good targets to improve differ-
ential diagnostic methods or even for vaccine develop-
ment.
Only around 20% of the T. cruzi chronically infected
patients develop symptomatic presentations such as car-
diac or digestive tract involvement and, despite the efforts
for many years, no effective prognostic markers are yet
available. Manifestations of Chagas disease range from
asymptomatic to subtle abnormalities seen on electrocar-Parasites & Vectors 2008, 1:20 http://www.parasitesandvectors.com/content/1/1/20
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diograms which may evolve to advanced congestive heart
failure and/or disabling megaesophageal or colonic syn-
dromes. However, the majority (~60%) of infected indi-
viduals present no clinical evidence of infection other
than positive serology. The reasons leading to such wide
variation of clinical presentations are not yet established
but are likely related to both host and parasite genetics
and to variation in host immunity [33,34]. Using ELISA
and western blot assays, Morgan et al. [23] reported a dif-
ference in the levels of some anti-T. cruzi epimastigote
antibody isotypes among patients with different clinical
presentations, suggesting that the type of antibodies pro-
duced by an individual could be related to their clinical
presentation.
Serological cross-reactivity between different infectious
etiological agents is well reported in the literature. Con-
sidering T. cruzi infection in humans, cross-reactions may
occur in distinct levels with toxoplasmosis, hanseniasis,
tuberculosis, auto-immune diseases, leishmaniasis as well
as with other trypanosomatid species as formerly reported
[15,20,29,30,35].
Recent studies have comparatively tested the use of T. cruzi
amastigote, epimastigote and trypomastigote forms from
two strains as antigens in diagnostic ELISA assays, having
observed that trypomastigote forms are as effective as epi-
mastigotes concerning specificity, sensitivity and antigen
stability [35,36]. In these studies, the authors discuss the
problems involving the use of infective trypomastigote
forms versus the possible clinical implications of detect-
ing anti-T. cruzi antibodies directed to the bloodstream
form, reinforcing the needs for the use of recombinant
antigens.
Considering the onus of Chagas disease in Latin and Cen-
tral America, regarding not only the costs related to treat-
ment and patient care but also the social implications,
and further considering the sympatric occurrence with T.
rangeli in wide geographical areas; the development of a
species-specific detection system able to differentiate both
parasite species is of utmost relevance [15]. As a result of
this study we believe that the use of trypomastigote forms
of both species as antigens for IFA will reduce false-posi-
tive diagnosis of Chagas disease in areas were T. rangeli
also occurs. The consequent increment on the costs of try-
pomastigote-based diagnosis will trade off against a
reduction of the costs associated with false-positive results
and a direct benefit in terms of human health.
The existing serological cross-reaction between T. cruzi
and T. rangeli due their antigenic similarity is indeed a
problem for diagnosis but it may be an interesting point
to address protective immunological effects on Chagas
disease [8,37,38]. Recently, Basso et al. [38] tested the effi-
cacy of T. rangeli vaccination in dogs using an emulsion of
epimastigote forms from a single strain of the parasite.
The challenge with T. cruzi blood trypomastigotes on vac-
cinated animals revealed a reduction of the period and
levels of parasitemia, concluding that the protective effect
is based on the high antigenic similarity between species
and that T. rangeli may be a good agent to induce protec-
tive immune response against T. cruzi in dogs in endemic
areas [38]. Despite promising results, this study does not
have considered the antigenic variability among distinct
strains and forms as well as the possible bias on diagnosis
of vaccinated individuals.
Indeed, T. rangeli is a good model to address the develop-
ment of both therapeutic or prophylactic vaccines, how-
ever, the antigenic variability among distinct species,
strains and forms must be observed while discussing the
use antigen-based vaccines [38-40] or even genetic vac-
cines [41].
Studies on the use of T. rangeli as a vaccine candidate for
T. cruzi infection have reported reduction in parasitemia,
clinical symptoms and mortality rates in experimental
models [38,39]. However, the use of distinct animal mod-
els with specific strains and life-cycle stages of parasite
inoculated seem to have influence on the results of both
diagnostic and vaccine development assays [15,38].
Conclusion
In conclusion, we recommend that positive sera for Cha-
gas disease be retested with T. rangeli antigens in areas
where overlapped distribution of these species occurs.
Even considering the drawbacks of associated costs and
safety issues on culturing infective forms, our results indi-
cates that the use of both T. cruzi and T. rangeli trypomas-
tigotes as antigens in IFA or IB assays will help to avoid
misdiagnosis of Chagas disease.
Further studies using 2D gel electrophoresis are in
progress to obtain the differentially expressed proteins for
identification by mass spectrometry. Because of the nature
by which they were defined such protein markers will
likely prove of interest both diagnostically and biologi-
cally.
Methods
Serum samples
Approximately 40 serum samples were used for indirect
immunofluorescence assays (IFA). Sera from chronic cha-
gasic patients with the cardiac (n = 26) or indeterminate
(n = 13) forms were obtained from two distinct cryobanks
(Laboratório de Protozoologia, Universidade Federal de
Santa Catarina, Florianópolis, SC – Brazil and Centro de
Referência para Doenças Infecciosas e Parasitárias, Uni-
versidade Federal de Minas Gerais, Belo Horizonte, MG –Parasites & Vectors 2008, 1:20 http://www.parasitesandvectors.com/content/1/1/20
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Brazil). These samples were collected from endemic areas
during the 50's and their use was approved by the UFSC
Ethics Committee. Four negative serum samples obtained
from each institution formed a pool that was used as a sin-
gle negative control in all assays. All samples had been
previously tested as individually negative by IFA using T.
cruzi epimastigote forms as antigens. Ten additional sera
recently obtained from acute chagasic patients (n = 5) [42]
and from patients with the digestive form (n = 5) of the
chagasic infection were also included in immunoblotting
(IB) assays, for which an informed consent approved by
the UFSC Ethics Committee was also obtained.
Parasites
T. rangeli Choachi strain and T. cruzi Y strain were used for
antigen preparation. For IFA, T. cruzi CL and T. rangeli SC-
58 strains were also included. All strains were grown in
LIT (Liver Infusion Tryptose) medium supplemented with
15% of fetal calf serum (FCS) at 27.5°C by weekly pas-
sages. Epimastigotes forms of both species were obtained
in the exponential growth phase in LIT medium. T. cruzi
culture trypomastigotes were obtained by infection of
Vero cells (ATCC-CCL81) in Dulbecco's modified Eagle's
Medium – DMEM (SIGMA, St. Louis), pH 7.4 supple-
mented with 10% FCS. Cells were maintained in 25 cm2
culture flasks (NUNC, Naperville) and infected with Y
strain blood trypomastigotes obtained from experimen-
tally infected Swiss mice. T. rangeli culture trypomastig-
otes of the Choachi strain were obtained by in vitro
differentiation in DMEM as previously described [43] and
purified by cation exchange chromatography using a CM-
cellulose column [44].
Indirect Immunofluorescent assay (IFA)
For antigen preparation, T. cruzi and T. rangeli epimastig-
otes and trypomastigotes were washed three times in
phosphate-buffered saline (PBS) supplemented with glu-
cose 0.1% (PBSG), pH 7.4 and fixed in paraformaldehyde
2% in PBS (v/v) for 2 hours at 4°C. Fixed parasites where
then washed twice in PBS pH 7.4, the final concentration
was adjusted to 1 × 106 parasites/ml in PBS supplemented
with 1% bovine serum albumin (BSA). The antigens were
then distributed (5 μl/well) in 12 well immunofluores-
cence slides (Knittel, Braunschweig), air dried and stored
at -20°C for periods no longer than 2 months.
Each patient sera was individually analyzed using dilu-
tions of 1:40, 1:80, 1:160, 1:320, 1:640 and 1:1,280 in
PBS pH 7.4. Positive control sera and negative control
serum pool were used at 1:40 dilution. After dilution, 10
μl of each serum was placed on each of the slides and
incubated for 30 min at 37°C. After incubation, slides
were washed twice in PBS for 10 min and incubated for 30
min with 15 μl/well of a FITC-labelled anti-human IgG
conjugate (Biolab, São Paulo) in 0.01% Evan's blue. After
a new wash in PBS, slides were then mounted with buff-
ered glycerine under cover slips for microscopic observa-
tion with an Olympus Bx40-FL microscope (Olympus,
Tokio). Sample titers were determined by the maximum
dilution where the fluorescent parasites could be detected.
All experiments were performed in duplicate and evalu-
ated by, at least, two independent observers. The obtained
results were compared by ANOVA and the means by the
Dunn's test, considering significant differences with p <
0.05.
Protein assays
A total of 1 × 108 cells of each parasite species, strains and
forms were obtained from cultures as described above.
Each was washed three times in PBS (10 min/2,000 × g)
and the pellet stored at -80°C. Also, 108 uninfected Vero
cells cultured as described before were washed three times
in PBS (10 min/2,000 × g) and the pellet stored at -80°C.
The pellets were then ressuspended in 100 μl of lysis
buffer (50 mM NaCl, 200 mM Tris-HCl pH 8.0, 1% Non-
idet P-40) and 2 μl of a mixture of protease inhibitors
(PMSF 44.2 mg/ml, pepstatin 68.6 μg/ml, TPCK 2.0 mg/
ml and TLCK 0.5 mg/ml). The samples were then centri-
fuged at 14.000 × g for one hour, at 4°C, and the superna-
tant containing the protein extracts was stored at -80°C.
Protein concentration was determined by the Bradford
method, using BSA as a protein standard.
The same amount of proteins extracts from T. cruzi and T.
rangeli epimastigotes and trypomastigotes, as well as from
Vero cells, were separated in 12% SDS-PAGE in a 10 cm ×
10 cm mini-gel system (Bio-Rad, Richmond) along with a
Protein MW Marker (Jena Bioscience, Jena). Briefly, sam-
ples of 50 μg of each protein extract were dissolved in an
equal volume of sample buffer (125 mM Tris-HCl, pH
6.8, 1.5% 2-mercaptoethanol, 2% SDS, 20% glycerol,
0.1% bromophenol blue) and boiled for 3 min, immedi-
ately transferred to ice for 3 min and then resolved at 100
V for approximately 2 h. The protein profiles were visual-
ized by standard Comassie brilliant blue staining and dig-
itally recorded.
The proteins separated by SDS-PAGE were then trans-
ferred onto a nitrocellulose membrane (Hybond-ECL,
Amersham Biosciences – GE Healthcare) at 25 V overnight
in buffer containing 25 mM Tris; 192 mM Glycine and
20% Methanol. After blotting, the membranes were
blocked with 5% fat free milk 0.1% PBS-Tween 20 for 1 h,
cut as vertical strips of 0.4–0.5 cm wide and individually
treated for 90 min at room temperature with each serum
sample (acute, indeterminate, cardiac and negative serum
pool control) diluted 1:3,000 in 0.1% PBS-Tween 20. The
strips were then treated for 90 min with anti-human IgG
conjugate labeled with peroxidase (H+L, Promega, Madi-
son) and the reaction developed using the ECL kit (Amer-Parasites & Vectors 2008, 1:20 http://www.parasitesandvectors.com/content/1/1/20
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sham Biosciences – GE Healthcare) according to the
manufacturer's indications.
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